The larger, longer trial failed to show significant results at all
He reported 2 days of vomiting and 1 week of ongoing nausea but didnt require hospital care
This article reports that discontinuation of semaglutide 2.4 mg is followed by weight regain, supporting the need for continued treatment to maintain weight loss
Wegovy (semaglutide) is a once-a-week injection thats approved by the Food and Drug Administration (FDA) to: Reduce excess body weight and maintain weight reduction in: Adults with a body mass index (BMI) of 30 or higher Adults with a BMI of 27 or higher who also have weight-related medical problems, such as high cholesterol or high blood pressure Adolescents ages 1217 who are at or above the 95th percentile on sex- and age-specific growth charts Reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and a BMI of 27 or higher Wegovy belongs to a family of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists)
They know your medical history, the medications you are taking, and your overall health goals
Your board-certified physician reviews your medical history, evaluates whether you are a candidate, and determines whether prescription weight loss medication is clinically appropriate for you